methylphenidate HCl ERCT

ApprovedWithdrawn

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Attention Deficit Hyperactivity Disorder (ADHD)

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Trial Timeline

Sep 25, 2018 → Dec 3, 2020

NCT ID

NCT03546400

About methylphenidate HCl ERCT

methylphenidate HCl ERCT is a approved stage product being developed by Pfizer for Attention Deficit Hyperactivity Disorder (ADHD). The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03546400. Target conditions include Attention Deficit Hyperactivity Disorder (ADHD).

What happened to similar drugs?

11 of 20 similar drugs in Attention Deficit Hyperactivity Disorder (ADHD) were approved

Approved (11) Terminated (1) Active (9)

✅atomoxetineEli LillyApproved

✅AtomoxetineEli LillyApproved

✅Atomoxetine HydrochlorideEli LillyApproved

🔄AtomoxetineEli LillyPhase 3

✅AtomoxetineEli LillyApproved

✅Atomoxetine hydrochloride + PlaceboEli LillyApproved

🔄CLONICEL (Clonidine HCl sustained release)ShionogiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03546400	Approved	Withdrawn	Sep 25, 2018	Dec 3, 2020	Attention Deficit Hyperactivity Disorder (ADHD)

Competing Products

20 competing products in Attention Deficit Hyperactivity Disorder (ADHD)

See all competitors

Product	Company	Stage	Hype Score
atomoxetine	Eli Lilly	Approved	39
Atomoxetine + Placebo	Eli Lilly	Phase 2/3	38
Atomoxetine	Eli Lilly	Approved	35
Atomoxetine Hydrochloride	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Phase 3	40
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine hydrochloride + Placebo	Eli Lilly	Approved	43
CLONICEL (Clonidine HCl sustained release)	Shionogi	Phase 3	40
Donepezil hydrochloride + Placebo	Eisai	Phase 3	40
LY2216684 + Methylphenidate + Placebo (tablet) + Placebo (capsule)	Eli Lilly	Phase 2/3	38
Atomoxetine + Placebo	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Pre-clinical	26
Atomoxetine Hydrochloride	Eli Lilly	Approved	43
Atomoxetine hydrochloride	Eli Lilly	Phase 3	40
Atomoxetine Hydrochloride + Placebo	Eli Lilly	Approved	43
atomoxetine	Eli Lilly	Phase 3	40
atomoxetine 0.5 mg/kg/day + placebo + atomoxetine 1.2 mg/kg/day + atomoxetine 1.2-1.4 mg/kg/day	Eli Lilly	Phase 3	40
Atomoxetine Hydrochloride	Eli Lilly	Approved	43
Atomoxetine Hydrochloride	Eli Lilly	Phase 3	40